cisplatin + necitumumab + pemetrexed

This is a combination regimen consisting of three drugs: - **Cisplatin**: A platinum-based chemotherapy agent that causes DNA crosslinking and inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. - **Necitumumab**: A recombinant human IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling involved in tumor cell proliferation and survival. - **Pemetrexed**: An antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes essential for the synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis. This combination has been investigated for use in non-small cell lung cancer (NSCLC), particularly as a first-line treatment. While necitumumab is FDA-approved only in combination with gemcitabine and cisplatin for metastatic squamous NSCLC, pemetrexed is approved primarily for non-squamous NSCLC. The specific triple combination of cisplatin + necitumumab + pemetrexed does not have an established or approved indication but may be explored in clinical research settings.

Brand names

Portrazza

Other names

necitumumab + pemetrexed + cisplatin